215 related articles for article (PubMed ID: 7902206)
1. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
Yahanda AM; Alder KM; Fisher GA; Brophy NA; Halsey J; Hardy RI; Gosland MP; Lum BL; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1624-34. PubMed ID: 1403040
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
[TBL] [Abstract][Full Text] [Related]
4. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
[TBL] [Abstract][Full Text] [Related]
5. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
González-Manzano R; Cid J; Brugarolas A; Piasecki CC
Br J Cancer; 1995 Nov; 72(5):1294-9. PubMed ID: 7577485
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett NL; Lum BL; Fisher GA; Brophy NA; Ehsan MN; Halsey J; Sikic BI
J Clin Oncol; 1994 Apr; 12(4):835-42. PubMed ID: 8151326
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
[TBL] [Abstract][Full Text] [Related]
13. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
Lacayo NJ; Lum BL; Becton DL; Weinstein H; Ravindranath Y; Chang MN; Bomgaars L; Lauer SJ; Sikic BI; Dahl GV
Leukemia; 2002 May; 16(5):920-7. PubMed ID: 11986955
[TBL] [Abstract][Full Text] [Related]
15. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
16. High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours.
Bisogno G; Cowie F; Boddy A; Thomas HD; Dick G; Pinkerton CR
Br J Cancer; 1998 Jun; 77(12):2304-9. PubMed ID: 9649150
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour.
Van de Vrie W; Gheuens EE; Durante NM; De Bruijn EA; Marquet RL; Van Oosterom AT; Eggermont AM
J Cancer Res Clin Oncol; 1993; 119(10):609-14. PubMed ID: 8101524
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Rowinsky EK; Smith L; Wang YM; Chaturvedi P; Villalona M; Campbell E; Aylesworth C; Eckhardt SG; Hammond L; Kraynak M; Drengler R; Stephenson J; Harding MW; Von Hoff DD
J Clin Oncol; 1998 Sep; 16(9):2964-76. PubMed ID: 9738565
[TBL] [Abstract][Full Text] [Related]
19. Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA.
Dietel M; Herzig I; Reymann A; Brandt I; Schaefer B; Bunge A; Heidebrecht HJ; Seidel A
J Cancer Res Clin Oncol; 1994; 120(5):263-71. PubMed ID: 7907333
[TBL] [Abstract][Full Text] [Related]
20. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines.
Stuart NS; Philip P; Harris AL; Tonkin K; Houlbrook S; Kirk J; Lien EA; Carmichael J
Br J Cancer; 1992 Nov; 66(5):833-9. PubMed ID: 1358168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
